Xi Li

Xi Li

Auto-generated profile, based on publicly available information

Xi Li

Sichuan University

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 October 2021 in Radiology
Verified
Journal Article
Closed access
XLXi Li
Xi Li
AHAbdullah Hagar
Abdullah Hagar
XWXin Wei
Xin Wei
FCFei Chen
Fei Chen
YLYijian Li
Yijian Li
CMChen Mao
Chen Mao
Primary mitral regurgitation and D-shaped annular circumference derived from multisection CT were independent predictors of less mitral regurgitation improvement after transcatheter aortic valve re... Background There are conflicting results over the improvement rate and predictors of mitral regurgitation in patients undergoing transcatheter aortic valve replacement (TAVR). Purpose To define the...

5 March 2023 in Aging Clinical and Experimental Research
Verified
Journal Article
Closed access
PDF file
LXLi Xi
Li Xi
ZXZhong Xuemei
Zhong Xuemei
YLYan Ling
Yan Ling
CCChen Changchun
Chen Changchun
HZHou Zhuo
Hou Zhuo
XWXin Wei
Xin Wei

13 May 2020 in Catheterization and Cardiovascular Interventions
Verified
Journal Article
Closed access
PDF file
TXTian‐Yuan Xiong
Tian‐Yuan Xiong
YLYan‐Biao Liao
Yan‐Biao Liao
YLYi‐Jian Li
Yi‐Jian Li
FCFei Chen
Fei Chen
XLXi Li
Xi Li
CMChen Mao
Chen Mao

3 March 2026 in Journal of the American Heart Association
Verified
Journal Article
Open access
YZYi Zhang
Yi Zhang
TXTianyuan Xiong
Tianyuan Xiong
YFYuan Feng
Yuan Feng
ZZZhengang Zhao
Zhengang Zhao
XWXin Wei
Xin Wei
CMChen Mao
Chen Mao

1 January 2026 in Journal of Interventional Cardiology
Verified
Journal Article
Open access
PDF file
TXTianyuan Xiong
Tianyuan Xiong
YZYi Zhang
Yi Zhang
FQFan Qiao
Fan Qiao
YFYuan Feng
Yuan Feng
ZZZhengang Zhao
Zhengang Zhao
CMChen Mao
Chen Mao
Background: Functional tricuspid regurgitation (TR) after previous left‐sided valve surgery (LSVS) represents a significant proportion of all isolated TR cases; tricuspid valve reoperation in such patients, often in the advanced stage of disease, is historically regarded as high‐risk. Percutaneous transcatheter–based therapies for TR emerge as a potential solution. We sought to verify the performance of the LuX‐Valve Plus system in patients with a history of LSVS. Methods: A post hoc analysis of patients enrolled in the first‐in‐man and confirmatory study and an investigator‐initiated trial of the LuX‐Valve Plus system was conducted. Multiple endpoints, including mortality, valve performance, and functional status, were compared between patients with or without a history of LSVS. Propensity score matching (PSM) was used to minimize baseline differences between groups. Results: The study included 153 patients, with 56 patients having prior LSVS. After PSM, there were a total of 46 matched pairs. All‐cause mortality at 6 months was similar between groups (2.38% vs. 0%, respectively). Less‐than‐moderate paravalvular leakage and central TR were consistently observed in approximately 85% and 95% of patients through 6 months. Patients after prior LSVS achieved similar functional outcome in terms of the proportion of patients in NYHA Class I–II at 6 months (81.25% vs. 95.83%, p = 0.221). The Kansas City Cardiomyopathy Questionnaire score improved significantly after the procedure. Conclusions: In this small‐scale study, transcatheter implantation of the LuX‐Valve Plus for TR appeared to be safe and effective in patients with a history of LSVS, showing lower short‐term mortality and a degree of TR correction comparable to surgical outcomes.

15 June 2025 in Catheterization and Cardiovascular Interventions
Verified
Journal Article
Closed access
YZYi Zhang
Yi Zhang
FCFei Chen
Fei Chen
YYYijun Yao
Yijun Yao
ZZZhongkai Zhu
Zhongkai Zhu
XLXi Li
Xi Li
MCMao Chen
Mao Chen